TerminatedNCT04708834
Long-term Safety Study of Adjunctive Troriluzole in Subjects With OCD
Medication studyAges 18–65Multiple countries
Understand this study
Who could participate?
This study is for people with OCD. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Chandler and 174 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 30, 2021
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 772
- Sponsor
- Biohaven Pharmaceuticals, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada, United Kingdom, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04708834
- Official title
Show the full official title
A Multicenter, Long-Term Open-Label Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Chandler, United States · Phoenix, United States · Little Rock, United States
143 more locations
- Anaheim, United States
- Bellflower, United States
- Beverly Hills, United States
- Colton, United States
- Costa Mesa, United States
- Culver City, United States
- Encino, United States
- Glendale, United States
- Imperial, United States
- Lancaster, United States
- Lemon Grove, United States
- Long Beach, United States
- Los Alamitos, United States
- Los Angeles, United States
- Newport Beach, United States
- Oakland, United States
- Oceanside, United States
- Orange, United States
- Redlands, United States
- Riverside, United States
- San Diego, United States
- San Jose, United States
- Santa Ana, United States
- Sherman Oaks, United States
- Stanford, United States
- Torrance, United States
- Upland, United States
- Denver, United States
- Hartford, United States
- New Haven, United States
- New London, United States
- Norwich, United States
- Apopka, United States
- Boca Raton, United States
- Coral Gables, United States
- Coral Springs, United States
- Fort Myers, United States
- Gainesville, United States
- Hialeah, United States
- Jacksonville, United States
- Lakeland, United States
- Lauderhill, United States
- Lutz, United States
- Maitland, United States
- Miami, United States
- Miami Gardens, United States
- Miami Springs, United States
- Naples, United States
- New Port Richey, United States
- North Bay Village, United States
- North Miami, United States
- North Miami Beach, United States
- Orange City, United States
- Orlando, United States
- Palmetto Bay, United States
- Pembroke Pines, United States
- Pinellas Park, United States
- Sweetwater, United States
- Tampa, United States
- Winter Park, United States
- Atlanta, United States
- Decatur, United States
- Savannah, United States
- Snellville, United States
- Boise, United States
- Chicago, United States
- Elgin, United States
- Libertyville, United States
- Naperville, United States
- Prairie Village, United States
- Bangor, United States
- Gaithersburg, United States
- Pikesville, United States
- Towson, United States
- Boston, United States
- Methuen, United States
- Springfield, United States
- Watertown, United States
- Ann Arbor, United States
- Flowood, United States
- O'Fallon, United States
- St Louis, United States
- Missoula, United States
- Las Vegas, United States
- Berlin, United States
- Cherry Hill, United States
- Toms River, United States
- Brooklyn, United States
- Cedarhurst, United States
- Great Neck, United States
- Mount Kisco, United States
- New York, United States
- Rochester, United States
- Staten Island, United States
- Fayetteville, United States
- Beavercreek, United States
- Canton, United States
- Cincinnati, United States
- Dayton, United States
- Oklahoma City, United States
- Tulsa, United States
- Allentown, United States
- Media, United States
- Philadelphia, United States
- Mt. Pleasant, United States
- Austin, United States
- Baytown, United States
- Bryan, United States
- Dallas, United States
- DeSoto, United States
- Fort Worth, United States
- Houston, United States
- Mesquite, United States
- Missouri City, United States
- Plano, United States
- San Antonio, United States
- Wichita Falls, United States
- Woodstock, United States
- Bellevue, United States
- Calgary, Canada
- Chatham, Canada
- Hamilton, Canada
- Kingston, Canada
- Toronto, Canada
- Florence, Italy
- Milan, Italy
- Naples, Italy
- Pisa, Italy
- Turin, Italy
- Amsterdam, Netherlands
- Leiden, Netherlands
- Barcelona, Spain
- Madrid, Spain
- Oviedo, Spain
- Salamanca, Spain
- Vigo, Spain
- Blackpool, United Kingdom
- Chertsey, United Kingdom
- Liverpool, United Kingdom
- London, United Kingdom
- Manchester, United Kingdom
- Milton Keynes, United Kingdom
- Tankersley, United Kingdom
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Biohaven Pharmaceuticals, Inc.
Does this study involve medication?
Yes. The study involves medication, including Troriluzole (BHV-4157).
Who can participate?
This study is for people with OCD. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
